Biotech, to time with a good feeling

Promising undervalued biotech companies offer an excellent opportunity for significant future returns. Waiting until the sector is back in the spotlight often results in a missed opportunity. As share prices will have risen by then.

Biotech, to time with a good feeling
Lees verder

UCB: An interesting biopharmaceutical growth story

UCB is a biopharma company with over 8 600 employees, headquartered in Brussels, Belgium The company develops and manufactures multiple medicines, sold in 40 countries. In this company showcase we describe why we think UCB is an interesting biopharmaceutical growth story, even after 95 years of existence.

UCB: An interesting biopharmaceutical growth story
Lees verder

Aescap Genetics Newsletter Q3 2022

From treatment of symptoms to cure. The number of genetic medicines that are so advanced in R&D that they are tested on humans has been increasing by an average of 27% per year since 2016.

Aescap Genetics Newsletter Q3 2022
Lees verder

Aescap Life Sciences Newsletter Q3 2022

Upward potential of portfolio further increased. The fund made a small positive net performance for the third quarter of 1,8%. Continuous poor market sentiment continued to depress share prices of our portfolio companies despite the present and expected future revenue and profit growth these innovative companies face.

Aescap Life Sciences Newsletter Q3 2022
Lees verder

Aescap Life Sciences Newsletter Q2 2022

Solid performance across portfolio. Due to a strong net performance of +13,2% since we published our NAV of mid June, the net performance of the fund for June ended at +8,8%.

Aescap Life Sciences Newsletter Q2 2022
Lees verder